HIV-associated anaemia before and after initiation of antiret-roviral therapy at ART centre of Minilik II Hospital, Addis Ababa, Ethiopia

Ethiopian Medical Journal

Volumn 50, Issue 1, 2012, Pages 13-21

  Adane, Asfaw ^a,b   Desta, Kassu ^a   Bezabih, Aknanaw ^a   Gashaye, Anteneh ^a   Kassa, Desta ^b  

^a ADDIS ABABA UNIVERSITY   (Ethiopia)

^b Ethiopian Health and Research Nutrition Institute   (Ethiopia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; ETHIOPIA; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PREVALENCE; RETROSPECTIVE STUDY; SEX RATIO;

ADULT; ANEMIA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; ETHIOPIA; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; PREVALENCE; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; YOUNG ADULT;

EID: 84861322327     PISSN: 00141755     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. WHO/UNAIDS. Global situations of HIV/AIDS. 2009. Available at: http://data.unaids.org/pub/GlobalReport/2009/2009-GR-ExecutiveSummary-en.pdf. accessed on Nov, 15, 2010.
2. Federal Ministry of Health, National HIV/AIDS Prevention and Control Office. AIDS in Ethiopia. 2006. Technical document for the sixth edition, pp 19.
3. Muhammad W. S. HIV associated Autoimmune Hemolytic Anemia: An update AIDS patient care and STDs. 2001;15(4):217.
4. Nadler JP, Wills TS, Somboonwit C, Vincent A, Leitz G, Marino K, et al,. Anemia prevalence among HIV patient: antiretroviral therapy and other risk factors. Poster: The 2nd IAS Conference on HIV Pathogenesis and Treatment, 2003; Abstract no. 1151
5. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the Multistate Adult and Adolescent Spectrum of HIV Disease Surveillance project. The adult/Adolescent spectrum of Disease Group Blood. 1998;91;301-8.
6. Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, et al, Anemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. Euro SIDA Study Group. AIDS. 1999;13(8):943-50.
7. Lundgren JD, Mocroft A, Gatell JM, Ledergerber B, Darmino MA, Hermans P, et al; A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA Study. J Infect Dis 2002;185:178-87.
8. Lewden C, Francois R, Cuzin L, Cailleton V, Louis V, Chene G, et al; Fcators Associated with Mortality in Human Immunodeficiency Virus Type 1-Infected Adults initataing Protease Inhibitors-Containing Therpay: Role of Education Level and Eraly Transaminase Level Elevation (APPROCO-ANRS EP 11 Study). J Infect Dis. 2002;186:5:710-4
9. Abrams DI, Steinhart C, Frascino R. Epoetin alpha therapy for anemia in HIV-infected Patients: impact on quality of life. Int J STD AIDS. 2000;11:659-65.
10. Grossman H, Bowers P, Leitz G. Once-weekly epoetin alfa (Procrit-) corrects hemoglobin and improves quality of life as effectively as three times-weekly dosing in HIV+ patients [poster ThPeB7381] In: Proceedings of the XIV International AIDS Conference (Barcelona). 2002; Stockholm: International AIDS Society.
11. Moore RD and Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29(1):54-7
12. Sara J, Amitis R, Duman S, Banafssheh M, Seyed Ahmed S. A crossectional study of Anemia in Human Immunodeficiency VIRUS Infected Patients in Iran. Archives of Iranian Medicine: 2009:12:2:145-50.
13. NAAC Review Published, December 4, 2007: anemia prevalence and correlates in HIV patients in the HAART Era.
14. Berhane K, Karim R, Cohen MH, Masri-Lavine L, Young M, Anastos K, et al. Impact of Highly Active Antiretroviral Therapy on Anemia and survival in a large cohort of HIV-infected Women: Women's Interagency HIV study. J Acquir Immune Defic Syndr. 2004;37:2:1245-52.
15. Servias J, Nkoghe D, Schmit JC, Arendt V, Robert I, Staub T, et al. HIV associated Hematologic disorders are correlated with plasma Viral Load and improve Under Highly Active Antiretroviral Therapy (Clinical sciences). J AIDS. 2001;28:3:221-5.
16. Omoregie R, Omokaro E. U, Palmer O, Ogefere H. O, Egbeobauwaye A, Adeghe J. E, et al; Prevalence of anemia among HIV infected patients in Benin City, Nigeria. Tanzania J of Health Research. 2009;11:1:1-4.
17. Campbell GR, Marftn AA, Lanciotti RS, Gubler DJ. West Nile Virus, Lancet infectious Disease, 2002;2(9):519-29.
18. Patterson K, Napravnik S, Eron J, Keruly J, Moore R. Effect of age and sex on immunological and virological responses to initial Highly Active Antiretroviral Therapy. HIV Med. 2007;8:6:40-10 (Abstract).
19. Richard D. S., Nina S., Robert S. K., Kenneth H. M., Paula S., Lytti G., et al; Highly Active Antiretroviral Therapy Associated with improved Anemia Among HIV-infected Women. AIDS PATEINT CARE and STDs. 2001;15:9:473-80.
20. Asgeir J, Ezra N, Bernard NJ, Leiv S, Mecky IM, Henry EA et al; Predictors of mortality in HIV infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis. 2008;8:52
21. Soria A, Lazzarin A. Antiretroviral treatment strategies and immune reconstitution in treatment-naive HIV-infected patients with advanced disease. Acquir Immune Defic Syndr. 2007;46:supp 1. 19-30
22. Buskin SE, Sullivan PS. Anemia and its treatment and outcomes in persons infected with human immunodeficiency virus. Transfusion: 2004;44:6:826-32.